Home/Filings/4/0001055726-25-000002
4//SEC Filing

KIES PETER 4

Accession 0001055726-25-000002

CIK 0001055726other

Filed

Feb 27, 7:00 PM ET

Accepted

Feb 28, 6:05 PM ET

Size

19.9 KB

Accession

0001055726-25-000002

Insider Transaction Report

Form 4
Period: 2025-02-26
Transactions
  • Award

    Restricted Stock Unit

    2025-02-27+31,90031,900 total
    Common Stock (31,900 underlying)
  • Exercise/Conversion

    Common Stock

    2025-02-26+3,99728,364 total
  • Exercise/Conversion

    Common Stock

    2025-02-26+5,01031,012 total
  • Exercise/Conversion

    Restricted Stock Unit

    2025-02-263,9970 total
    Common Stock (3,997 underlying)
  • Tax Payment

    Common Stock

    2025-02-26$1.98/sh2,362$4,67726,002 total
  • Tax Payment

    Common Stock

    2025-02-26$1.98/sh2,960$5,86128,052 total
  • Exercise/Conversion

    Restricted Stock Unit

    2025-02-265,01010,019 total
    Common Stock (5,010 underlying)
  • Award

    Common Stock Option

    2025-02-27+39,05039,050 total
    Exercise: $1.94From: 2025-02-27Exp: 2035-02-27Common Stock (39,050 underlying)
Holdings
  • Common Stock

    (indirect: By Spouse)
    375
Footnotes (6)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 11,991 restricted stock units granted on February 26, 2022 was as follows: 3,997 shares vested on February 26, 2023; 3,997 shares vested on February 26, 2024; and 3,997 shares vested on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
  • [F2]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.
  • [F3]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 is as follows: 5,010 shares vested on February 26, 2025; 5,010 shares will vest on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
  • [F4]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (3) herein.
  • [F5]The vesting schedule for the 39,050 options is as follows: 19,525 shares vested on February 27, 2025 and 19,525 shares will vest on February 26, 2026.
  • [F6]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 31,900 restricted stock units granted on February 27, 2025 is as follows: 10,634 shares will vest on February 26, 2026; 10,633 shares will vest on February 26, 2027; and 10,633 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Issuer

INOVIO PHARMACEUTICALS, INC.

CIK 0001055726

Entity typeother

Related Parties

1
  • filerCIK 0001259780

Filing Metadata

Form type
4
Filed
Feb 27, 7:00 PM ET
Accepted
Feb 28, 6:05 PM ET
Size
19.9 KB